1048 related articles for article (PubMed ID: 27404965)
21. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.
Foster GR; Irving WL; Cheung MC; Walker AJ; Hudson BE; Verma S; McLauchlan J; Mutimer DJ; Brown A; Gelson WT; MacDonald DC; Agarwal K;
J Hepatol; 2016 Jun; 64(6):1224-31. PubMed ID: 26829205
[TBL] [Abstract][Full Text] [Related]
22. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
[TBL] [Abstract][Full Text] [Related]
23. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.
Fernández Carrillo C; Lens S; Llop E; Pascasio JM; Crespo J; Arenas J; Fernández I; Baliellas C; Carrión JA; de la Mata M; Buti M; Castells L; Albillos A; Romero M; Turnes J; Pons C; Moreno-Planas JM; Moreno-Palomares JJ; Fernández-Rodriguez C; García-Samaniego J; Prieto M; Fernández Bermejo M; Salmerón J; Badia E; Salcedo M; Herrero JI; Granados R; Blé M; Mariño Z; Calleja JL
Hepatology; 2017 Jun; 65(6):1810-1822. PubMed ID: 28170112
[TBL] [Abstract][Full Text] [Related]
24. Safety of Direct-Acting Antiviral Therapy Regarding Renal Function in Post-Liver Transplant Patients Infected with Hepatitis C Virus and a 100% 12-Week Sustained Virologic Response-A Single-Center Study.
Peschel G; Moleda L; Baier L; Selgrad M; Schmid S; Scherer MN; Müller M; Weigand K
Transplant Proc; 2018 Jun; 50(5):1444-1450. PubMed ID: 29880368
[TBL] [Abstract][Full Text] [Related]
25. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis C Virus Clearance in Older Adults.
Ippolito AM; Iacobellis A; Milella M; Conti F; Messina V; Valvano MR; Niro GA; Morisco F; Barone M; Termite AP; Brancaccio G; Andriulli A
J Am Geriatr Soc; 2018 Jan; 66(1):85-91. PubMed ID: 29135030
[TBL] [Abstract][Full Text] [Related]
27. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
[TBL] [Abstract][Full Text] [Related]
29. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130
[TBL] [Abstract][Full Text] [Related]
30. Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.
Tahata Y; Hikita H; Mochida S; Enomoto N; Ido A; Kuroda H; Miki D; Kurosaki M; Hiasa Y; Sakamori R; Kawada N; Yamashita T; Suda G; Yatsuhashi H; Yoshiji H; Kato N; Takami T; Nakao K; Matsuura K; Asahina Y; Itoh Y; Tateishi R; Nakamoto Y; Kakazu E; Terai S; Shimizu M; Ueno Y; Akuta N; Miyazaki M; Nozaki Y; Kabayama M; Sobue S; Moriuchi A; Miyaki T; Kodama T; Tatsumi T; Yamada T; Takehara T
J Gastroenterol; 2023 Dec; 58(12):1211-1221. PubMed ID: 37831182
[TBL] [Abstract][Full Text] [Related]
31. Impact of sustained virologic response on short-term clinical outcomes in hepatitis C-related cirrhosis.
Bashir MH; Fazili J; Madhoun MF; Kanagala R; Chen S; Nusrat S
Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):296-301. PubMed ID: 29200006
[TBL] [Abstract][Full Text] [Related]
32. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
Christensen S; Buggisch P; Mauss S; Böker KHW; Schott E; Klinker H; Zimmermann T; Weber B; Reimer J; Serfert Y; Wedemeyer H
Addiction; 2018 May; 113(5):868-882. PubMed ID: 29359361
[TBL] [Abstract][Full Text] [Related]
33. Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?
Hanafy AS; Bassiony MA; Basha MAA
Hepatol Int; 2019 Mar; 13(2):165-172. PubMed ID: 30758786
[TBL] [Abstract][Full Text] [Related]
34. Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study.
Wong YJ; Tran S; Huang CF; Hsu YC; Preda C; Toyoda H; Liu J; Jun DW; Landis C; Huang DQ; Gila A; Negoita L; Yasuda S; Tseng CH; Tsai PC; Uojima H; Nozaki A; Chuma M; Atsukawa M; Ishigami M; Itokawa N; Iio E; Lam CP; Watanabe T; Asai A; Yokohama K; Abe H; Enomoto M; Kawada N; Tamori A; Lee DH; Jun MJ; Do S; Vo DKH; Liu L; Li J; Ji F; Wang W; Li Y; Wang X; Guo F; Xu Q; Jing L; Ye Q; Pan H; Zhang J; Wen X; Wang Q; Ren H; Cai D; Shang J; Liu J; Lu C; Zang W; Li J; Niu J; Zhang M; Wu C; Huang R; Maeda M; Nakanishi A; Yeh ML; Chuang WL; Huang JF; Dai C; Ishikawa T; Takaguchi K; Senoh T; Trinh HN; Takahashi H; Eguchi Y; Quek SXZ; Haga H; Ogawa E; Wong G; Buti M; Fukunishi S; Ueno Y; Yuen MF; Tanaka Y; Lim SG; Cheung R; Yu ML; Nguyen MH
Hepatol Int; 2023 Oct; 17(5):1150-1161. PubMed ID: 37273170
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.
Perelló C; Carrión JA; Ruiz-Antorán B; Crespo J; Turnes J; Llaneras J; Lens S; Delgado M; García-Samaniego J; García-Paredes F; Fernández I; Morillas RM; Rincón D; Porres JC; Prieto M; Lázaro Ríos M; Fernández-Rodríguez C; Hermo JA; Rodríguez M; Herrero JI; Ruiz P; Fernández JR; Macías M; Pascasio JM; Moreno JM; Serra MÁ; Arenas J; Real Y; Jorquera F; Calleja JL;
J Viral Hepat; 2017 Mar; 24(3):226-237. PubMed ID: 27976491
[TBL] [Abstract][Full Text] [Related]
36. Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis.
McDonald SA; Pollock KG; Barclay ST; Goldberg DJ; Bathgate A; Bramley P; Dillon JF; Fraser A; Innes HA; Kennedy N; Morris J; Went A; Hayes PC; Hutchinson SJ
J Viral Hepat; 2020 Mar; 27(3):270-280. PubMed ID: 31696575
[TBL] [Abstract][Full Text] [Related]
37. Assessment of factors affecting response of direct-acting antivirals in chronic hepatitis C patients.
Jain N; Garg R; Singh GP; Kaur S; Chawla SPS; Padda P
Ann Afr Med; 2023; 22(4):456-464. PubMed ID: 38358146
[TBL] [Abstract][Full Text] [Related]
38. Platelet Count Improvement after Chronic Hepatitis C Treatment among Cirrhotic Patients Who Achieved Sustained Virological Response: Realworld Results from 2186 Patients in Egypt.
Badawi R; Soliman S; Aboali L; Elkadeem M; Elfert A; Elguindy AMA; Ullah MS; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2021; 21(7):1300-1305. PubMed ID: 32940191
[TBL] [Abstract][Full Text] [Related]
39. Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis.
Gambato M; Canini L; Lens S; Graw F; Perpiñan E; Londoño MC; Uprichard SL; Mariño Z; Reverter E; Bartres C; González P; Pla A; Costa J; Burra P; Cotler SJ; Forns X; Dahari H
Liver Int; 2019 May; 39(5):826-834. PubMed ID: 30499631
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
